Should we edit human embryos' genomes, and if so then how?
By Dieter Egli,
BioNews [cites CGS' Marcy Darnovsky]
| 07. 12. 2021
I recently received a thoughtful letter from a college student I do not know – I'll call her Claudia* – who took the time to reach out to me with her perspective on heritable genome editing in embryos. The promise of this new technology is that it could fix disease-causing mutations in all cells of the body before damage occurs, and the correction would be passed on to future generations as well.
My laboratory at Columbia University, New York performs basic research to better understand early human development with the goal of benefiting patients with heritable diseases. Last fall, we published an article in Cell about using CRISPR/Cas9 to potentially correct a blindness-causing mutation in embryos; we discovered that the use of this technology could lead to unintended loss of additional genetic material. Our findings were discussed in national and international media, and had apparently caught Claudia's attention. I reference Claudia's letter here, as I believe that many people share the hopes and concerns she expressed, and because they also in fact align with my own scientific views.
My...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Susanna Smith, Genetic Frontiers | 07.28.2025
Key Topics
How does the American far right view genetics and genetic technologies?
What is the history of the American cultural pursuit of trying to choose smarter children? What has science shown us about the relationship of heredity and intelligence...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...